Korean J Hematol.  2005 Sep;40(3):188-191. 10.5045/kjh.2005.40.3.188.

A Case of Extramedullary Progression Despite of Serologic Improvement in a Patient Treated with Thalidomide for Multiple Myeloma

Affiliations
  • 1Department of Internal Medicine, Sanggyepaik Hospital, Inje University College of Medicine, Seoul, Korea. yjyuh@sanggyepaik.ac.kr
  • 2Department of Laboratory Medicine, Sanggyepaik Hospital, Inje University College of Medicine, Seoul, Korea.

Abstract

Thalidomide is an anti-angiogenic agent widely used in patients with multiple myeloma. The response to therapy is commonly monitored using serum and/or urine M protein, as these are known to reflect the tumor burden. Although extramedullary plasmacytomas are tissues with high neovascularization, it has been suggested in some reports that the response to thalidomide in these patients may be inferior, despite changes in the serum M protein level. Herein, we report the case of a patient who newly developed hepatosplenic extramedullary plasmacytoma, despite reduction in the serum M protein level following thalidomide treatment.

Keyword

Thalidomide; Multiple myeloma; Extramedullary plasmacytoma
Full Text Links
  • KJH
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr